Soricimed To Select Partner in 2016
Assuming all goes well with its Phase 1 trials this year, Sackville, N.B.-based Soricimed Biopharma Inc. expects to select a major drug-maker as a partner with which it can take its flagship product Soricidin through Phase 2 trials.
SOR-C13 is a peptide, or a naturally occurring biological molecule, that binds to TRPV6, a calcium channel found in a cancer cell and deprives the cell of calcium, thereby killing the tumour. Soricimed hopes to establish that it is an effective means of treating cancer with minimal suffering for the patient.
The company is now conducting trials with about 20